Tag Archives: onetouch

Lilly Cuts Non-branded Lispro Prices By 40%; Positive Ph1 Data for New GLP-1RA Asset; Lifescan Presents Tu Salud Trial Data in Hispanic Population; EASD 2021 Key Press Releases (Sept 28)

On the second day of EASD 2021, three key press releases were observed from Lilly, Altimmune, and Lifescan. Below FENIX provides insights and context for the respective announcements.

About The Author

Matthew Maryniak

|
President of Fenix Group International

Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.

If you receive our email blasts, you already have an account.

Purchase Blast$599.00

You can read the article’s full content online after purchase.

Novo Nordisk Center for Genomic Mechanisms of Disease Launched; Lifescan and Welldoc Partnership; Xeris Approved to Acquire StrongBridge Pharma; Oramed Reaches 50% Enrollment in NASH

A series of cardiometabolic-related news items have been observed: the Novo Nordisk Foundation and the Broad Institute of MIT and Harvard announced the launch of the Novo Nordisk Foundation Center for Genomic Mechanisms of Disease; Lifescan and Welldoc announced a partnership to integrate Welldoc’s chronic condition platform into the OneTouch Solutions portal; Xeris announced it received stockholder approval for the previously announced proposed acquisition of Strongbridge Biopharma; and Oramed announced it has reached over 50% enrollment in the Ph2 trial evaluating its oral insulin (ORMD-0801) in T2DM patients with NASH. Below, FENIX provides highlights and insights for the respective news items.

About The Author

Matthew Maryniak

|
President of Fenix Group International

Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.

If you receive our email blasts, you already have an account.

Purchase Blast$599.00

You can read the article’s full content online after purchase.

Does Lifescan’s Expanded Partnership with Cecelia Health Signal a New Business Model to Set Up for an Acquisition by Livongo?

Lifescan and Cecelia Health announced the expansion of a multi-year partnership to offer users a fully integrated live telehealth service with the OneTouch Reveal app. Recall, Lifescan and Cecelia Health initially entered into the partnership in October 2020 starting with text-based coaching. According to the press release, Lifescan and Cecelia Health will launch a new, live Certified Diabetes Care and Education Specialists (CDCES) telehealth service through the OneTouch Reveal app which will be fully integrated into OneTouch Solutions. Below, FENIX provides thoughts on Lifescan’s apparent new strategy to expand its business model beyond traditional PBM reimbursement to either remain competitive or become attractive as an acquisition target.

About The Author

Matthew Maryniak

|
President of Fenix Group International

Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.

If you receive our email blasts, you already have an account.

Purchase Blast$599.00

You can read the article’s full content online after purchase.